The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group

Tuberculosis (TB) is still responsible for the deaths of >1 million people yearly worldwide, and therefore its correct diagnosis is one of the key components of any TB eradication programme. However, current TB diagnostic tests have many limitations, and improved diagnostic accuracy is urgently n...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:European respiratory review Ročník 31; číslo 163; s. 210218
Hlavní autoři: Melkie, Solomon Tibebu, Arias, Lilibeth, Farroni, Chiara, Jankovic Makek, Mateja, Goletti, Delia, Vilaplana, Cristina
Médium: Journal Article
Jazyk:angličtina
Vydáno: England European Respiratory Society 31.03.2022
Témata:
BCG Vaccine
Humans
Mycobacterium tuberculosis
Reviews
Tuberculosis - diagnosis
Tuberculosis - drug therapy
Tuberculosis - prevention & control
Tuberculosis Vaccines
Tuberculosis, Pulmonary - diagnosis
Tuberculosis, Pulmonary - drug therapy
Tuberculosis, Pulmonary - prevention & control
ISSN:0905-9180, 1600-0617, 1600-0617
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Tuberculosis (TB) is still responsible for the deaths of >1 million people yearly worldwide, and therefore its correct diagnosis is one of the key components of any TB eradication programme. However, current TB diagnostic tests have many limitations, and improved diagnostic accuracy is urgently needed. To improve the diagnostic performance of traditional serology, a combination of different Mycobacterium tuberculosis (MTB) antigens and different antibody isotypes has been suggested, with some showing promising performance for the diagnosis of active TB. Given the incomplete protection conferred by bacille Calmette–Guérin (BCG) vaccination against adult pulmonary TB, efforts to discover novel TB vaccines are ongoing. Efficacy studies from advanced TB vaccines designed to stimulate cell-mediated immunity failed to show protection, suggesting that they may not be sufficient and warranting the need for other types of immunity. The role of antibodies as tools for TB therapy, TB diagnosis and TB vaccine design is discussed. Finally, we propose that the inclusion of antibody-based TB vaccines in current clinical trials may be advisable to improve protection.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0905-9180
1600-0617
1600-0617
DOI:10.1183/16000617.0218-2021